Investigational pharmacologic treatment for liver disease
| Autor: | Kenneth M. Shermock, Zobair M. Younossi, Lori L Siatkosky |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Hepatitis C virus medicine.disease_cause Gastroenterology Primary sclerosing cholangitis Liver disease Pegylated interferon Internal medicine medicine Animals Humans Technology Pharmaceutical Pharmacology (medical) Pharmacology Hepatitis B virus Clinical Trials as Topic business.industry Liver Diseases Drugs Investigational General Medicine Hepatitis C medicine.disease Virology Ursodeoxycholic acid Steatohepatitis business medicine.drug |
| Zdroj: | Expert Opinion on Investigational Drugs. 11:1281-1293 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1517/13543784.11.9.1281 |
| Popis: | Liver disease can cause significant morbidity and mortality. Few pharmacological options exist for these diseases, however, new agents are in development and older agents are being evaluated for new indications. Several new nucleoside and nucleotide analogues are being developed to treat hepatitis B virus infection. Pegylated interferons have been developed for hepatitis C infection. Ursodeoxycholic acid has recently been implicated in the treatment of liver disease, including non-alcoholic steatohepatitis and primary sclerosing cholangitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|